Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

In this Spotlight On Lower-Risk MDS, learn more about:

✓ Updates on risk-stratification & disease classification

✓ Recognizing ESA failure, and when to switch therapy

✓ The latest therapy updates for LR-MDS beyond ESAs

The diagnosis and risk-stratification of patients with MDS has moved forward in recent years
to include the identification of several genomic targets1

Unmet needs in LR-MDS: RBC transfusion-dependence

Rena Buckstein, MD, FRCPC
Sunnybrook Research Institute, Toronto, Canada

Highlights in LR-MDS
at the ASH 2023 meeting

Thomas Cluzeau, MD, PhD
Central University Hospital of Nice, Nice, France

Revisions to the ICC and WHO classifications of AML and MDS

Sanam Loghavi, MD
MD Anderson Cancer Center, Houston, TX

Sequencing of agents
in LR-MDS

Guillermo Garcia-Manero, MD
MD Anderson Cancer Center, Houston, TX

Novel agents being explored from ASH 2023 and beyond

Amer Zeidan, Jan Bewersdorf, Maximilian Stahl, Yasmin Abaza, and Yazan Madanat

Emerging treatment options for patients with ESA-refractory MDS

Eva Hellström-Lindberg, MD, PhD
Karolinska University Hospital, Stockholm, Sweden

Advances in LR-MDS and HR-MDS in 2023 and beyond

Amer Zeidan, MBBS
Yale Cancer Center, New Haven, CT

Potential MDS targets beyond HMAs

Aditi Shastri, MD
Montefiore Medical Center, Bronx, NY

Diagnosis, risk stratification and treatment of LR-MDS

Leading experts Sanam Loghavi, MD Anderson Cancer Center, Houston, TX, and Rami Komrokji, Moffitt Cancer Center, Tampa, FL, discuss recent advances in the diagnosis, risk stratification and treatment of LR-MDS in this webinar available to view on demand.

Approaching ESA failure in patients with LR-MDS

The current standard of care for patients with transfusion-dependent LR-MDS and symptomatic anemia is ESAs.2 However, responses are limited, with patients at the eventual risk of ESA failure.2

Valeria Santini, MD, University of Florence, Florence, Italy, comments on factors that influence patient responses to ESAs, how to approach ESA failure in patients with lower-LR-MDS, and next steps for these patients.

Latest updates in the treatment of LR-MDS beyond ESAs
MEDALIST: luspatercept in ESA-intolerant/refractory LR-MDS

Valeria Santini, MD
University of Florence, Florence, Italy

Canakinumab plus darbepoetin for
LR-MDS following ESA failure

David Sallman, MD
Moffitt Cancer Center, Tampa, FL

IMerge trial: the disease-modifying potential of imetelstat in LR-MDS

Uwe Platzbecker, MD
University of Leipzig, Leipzig, Germany

Canakinumab with darbepoetin in patients who are ESA-refractory

Jeffrey Lancet, MD
Moffitt Cancer Center, Tampa, FL

Imetelstat for LR-MDS:
insights from the IMerge trial

Valeria Santini, MD
University of Florence, Florence, Italy

Luspatercept trials: COMMANDS, MEDALIST and ELEMENTS-MDS

Amer Zeidan, MBBS
Yale Cancer Center, New Haven, CT

See ClinicalTrials.gov for the latest information on the Phase III COMMANDS and IMerge trials in LR-MDS

Phase I/II trials in LR-MDS

Current and emerging treatment options for LR-MDS-associated anemia following ESA failure
Matteo Della Porta • 13 Jun 2023
The impact of IDH mutations in MDS & evaluating the role of IDH inhibitors
David Sallman • 20 Mar 2023
Phase II trial of AG-946 in patients with low-risk MDS and anemia
Uwe Platzbecker • 9 Dec 2022
Insights into the REPAIR-MDS trial: danazol vs VBaP in lower-risk MDS
Manoj Raghavan • 23 Apr 2023
The efficacy of low-dose ASTX727 in low-risk MDS
Guillermo Garcia-Manero • 4 May 2023
Overall survival of patients following treatment with luspatercept in the MEDALIST trial
Valeria Santini • 12 Dec 2022
Key highlights in MDS: treating lower-risk & higher-risk disease, trial updates, and more
Andrew Brunner et al. • 12 Dec 2022
Challenges with diagnosing MDS and future outlooks
Manoj Raghavan • 23 Apr 2023

Sources

  1. Garcia-Manero, G. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol 2023;98(8):1307–1325.
  2. Brunner, AM, et al. Management of patients with lower-risk myelodysplastic syndromes. Blood Cancer J 2022;12:166.

Glossary

ESA, erythropoietin-stimulating agent; ICC, International Consensus Classification; LR, lower risk; MDS, myelodysplastic syndromes; WHO, World Health Organization

 

This educational activity has received independent medical education support from
Bristol Myers Squibb. This supporter has no influence over the production of the content.

 

The content of VJHemOnc is intended for healthcare professionals